GAA
CSTL icon

Green Alpha Advisors’s Castle Biosciences CSTL Stock Holding History

Green Alpha Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Sell
9,941
-4
-0% -$89 0.16% 94
2026
Q1 		$244K Sell
9,945
-291
-3% -$9.53K 0.24% 84
2025
Q4 		$398K Buy
10,236
+698
+7% +$22.5K 0.36% 83
2025
Q3 		$217K Buy
+9,538
New +$194K 0.21% 88
2025
Q1 		– Sell
-9,327
Closed -$249K – 121
2024
Q4 		$249K Buy
+9,327
New +$284K 0.2% 120

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Green Alpha Advisors's CSTL Position: Q2 2026 in Review

Green Alpha Advisors reduced its Castle Biosciences (CSTL) stake by 0.04% in Q2 2026, selling an estimated $89 and leaving 9,941 shares worth $237K. The position accounts for 0.16% of the portfolio, ranked #94.

Green Alpha Advisors first reported a position in CSTL in Q4 2024 and has held it in 5 quarters since. The position peaked at $398K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Green Alpha Advisors held 9,941 shares of Castle Biosciences worth $237K as of Q2 2026.
  • Green Alpha Advisors sold 4 Castle Biosciences shares in Q2 2026, an estimated $89.
  • Castle Biosciences made up 0.16% of Green Alpha Advisors's portfolio in Q2 2026, its #94 holding.
  • Green Alpha Advisors first reported a position in Castle Biosciences in Q4 2024 and has held it in 5 quarters since.
  • Green Alpha Advisors's Castle Biosciences position peaked at $398K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.